首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

2054171

病毒疫苗市場規模、佔有率和成長分析：按疫苗類型、疾病類型、給藥途徑、年齡層、分銷管道、最終用戶和地區分類－2026年至2033年產業預測

Viral Vaccines Market Size, Share, and Growth Analysis, By Vaccine Type, By Disease Type, By Route of Administration, By Age Group, By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2026年05月26日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球病毒疫苗市場價值 675 億美元，預計到 2025 年將成長至 720.9 億美元，到 2033 年將成長至 1220.2 億美元，在預測期（2026-2033 年）內複合年成長率為 6.8%。

全球病毒疫苗市場的主要驅動力是人們對可靠且擴充性的免疫解決方案成長要素的需求，這源於應對持續爆發的感染疾病疫情和為應對大流行病做好準備的需要。該市場涵蓋疫苗開發的各個方面，包括研發、生產和分銷，凸顯了疫苗在拯救生命和確保醫療衛生系統韌性方面發揮的關鍵作用。創新一直是市場擴張的核心驅動力，疫苗發展歷程經歷了從傳統活病毒疫苗疫苗和去活化疫苗到先進的重組疫苗和mRNA技術的歷史性演變。人工智慧（AI）透過簡化抗原發現、改進候選疫苗設計和最佳化臨床試驗計劃，加速了疫苗的研發，從而縮短了研發週期並降低了成本。這些進步有助於擴大疫苗供應，尤其是在中低收入國家，並增強應對季節性疫情和新出現的病毒威脅的準備能力。

全球病毒疫苗市場成長要素

全球病毒疫苗市場的主要促進因素之一是病毒感染疾病的日益普遍和新興流行病威脅的不斷增加，迫切需要研發和推廣有效的疫苗。流感、肝炎和人類免疫力缺乏病毒（HIV）等病毒性疾病發病率的上升，以及大眾對疫苗接種益處的認知不斷提高，都在推動對創新疫苗解決方案的需求。此外，生物技術和調查方法的進步正在加速疫苗研發進程，從而能夠快速應對新出現的病毒威脅，並促進政府、醫療機構和製藥公司之間的合作。

全球病毒疫苗市場面臨的限制因素

全球病毒疫苗市場的主要限制因素之一是日益嚴重的“疫苗猶豫”，這源於對醫療體系的錯誤訊息和不信任。這種不願接種疫苗的心理會導致疫苗接種率下降，降低免疫規劃的有效性，並可能引發疫苗可預防疾病的捲土重來。此外，監管方面的挑戰以及疫苗研發和核准的複雜要求也會阻礙新型病毒疫苗及時上市。這些因素綜合起來可能會減緩病毒疫苗市場的成長，並對旨在控制病毒感染疾病的公共衛生措施產生影響。

全球病毒疫苗市場趨勢

全球病毒疫苗市場正經歷一場變革性趨勢，這主要得益於基於平台的疫苗創新，該創新利用多功能技術實現快速抗原交換和迭代最佳化。這種方法使製造商能夠針對不同的病毒標靶重新設計遞送系統，從而顯著加快產品線多元化，並縮短從概念到臨床試驗的時間。通用生產流程帶來的營運柔軟性和產能運轉率的提高，對那些優先考慮具有可預測商業化前景的平台產品組合的投資者和合作夥伴極具吸引力。隨著策略聯盟的形成、市場覆蓋範圍的擴大、從研發到上市的流程的簡化，該行業已做好準備，在瞬息萬變的醫療保健環境中實現顯著成長和適應性提升。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

Pfizer
Moderna
GlaxoSmithKline
Sanofi
Merck & Co.
AstraZeneca
Johnson & Johnson
Bharat Biotech
Serum Institute of India
Sinovac Biotech
Sinopharm
CanSino Biologics
Novavax
CSL Seqirus
Emergent BioSolutions
Valneva
BioNTech
CureVac
Panacea Biotec
Biological E.

結論與建議

簡介目錄

Product Code: SQMIG35I2671

Global Viral Vaccines Market size was valued at USD 67.5 Billion in 2024 and is poised to grow from USD 72.09 Billion in 2025 to USD 122.02 Billion by 2033, growing at a CAGR of 6.8% during the forecast period (2026-2033).

The global viral vaccines market is primarily driven by an increasing need for reliable and scalable immunization solutions in response to ongoing outbreaks and the necessity for pandemic preparedness. This market encompasses all aspects of vaccine development, including research, manufacturing, and distribution, highlighting the vital role vaccines play in saving lives and ensuring healthcare system resilience. With a historical evolution from traditional live and inactivated vaccines to advanced recombinant and mRNA technologies, innovation has become central to market expansion. Artificial intelligence enhances vaccine development by streamlining antigen discovery, improving candidate design, and refining trial planning, which accelerates timelines and decreases costs. These advancements facilitate broader distribution, particularly in low and middle-income countries, and enhance readiness for seasonal updates and emerging viral threats.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Viral Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Viral Vaccines Market Segments Analysis

Global viral vaccines market is segmented by vaccine type, disease type, route of administration, age group, distribution channel, end user and region. Based on vaccine type, the market is segmented into Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, Viral Vector Vaccines, mRNA Vaccines and Others. Based on disease type, the market is segmented into Influenza, COVID-19, Hepatitis, Human Papillomavirus (HPV), Measles, Mumps & Rubella (MMR), Varicella and Others. Based on route of administration, the market is segmented into Intramuscular, Oral, Intranasal and Subcutaneous. Based on age group, the market is segmented into Pediatric, Adult and Geriatric. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Government Supply Programs and Others. Based on end user, the market is segmented into Hospitals, Vaccination Centers, Clinics and Public Health Agencies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Viral Vaccines Market

One of the key market drivers for the Global Viral Vaccines Market is the increasing prevalence of viral infections and emerging pandemic threats, which necessitate the development and deployment of effective vaccines. The rising incidence of diseases caused by viruses, such as influenza, hepatitis, and human immunodeficiency virus (HIV), coupled with the growing awareness of vaccination benefits among populations, propels demand for innovative vaccine solutions. Additionally, advancements in biotechnology and research methodologies are accelerating vaccine development processes, allowing for rapid responses to emerging viral threats and fostering collaborations between governments, healthcare organizations, and pharmaceutical companies.

Restraints in the Global Viral Vaccines Market

One key market restraint for the global viral vaccines market is the growing prevalence of vaccine hesitancy, driven by misinformation and distrust in healthcare systems. This reluctance to vaccinate can result in lower immunization rates, limiting the effectiveness of vaccination programs and potentially allowing for the resurgence of vaccine-preventable diseases. Additionally, regulatory challenges and the complex requirements for vaccine development and approval can hinder the timely introduction of new viral vaccines into the market. Together, these factors may slow the growth of the viral vaccines market, impacting public health initiatives aimed at controlling viral infections.

Market Trends of the Global Viral Vaccines Market

The Global Viral Vaccines market is witnessing a transformative trend driven by platform-based vaccine innovation, which utilizes versatile technologies for rapid antigen swapping and iterative optimization. This approach allows manufacturers to repurpose delivery systems for various viral targets, significantly accelerating pipeline diversification and reducing timeframes from concept to clinical testing. Enhanced operational flexibility and capacity utilization emerge from common production processes, appealing to investors and collaborators who prioritize platform portfolios for their predictable commercialization prospects. As strategic alliances form, they enhance market reach and facilitate smoother transitions from research to market availability, positioning the sector for substantial growth and adaptability in a dynamic healthcare landscape.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape
Value Chain Analysis
Case Studies
Technology Assessment
Customer & Buying Criteria Analysis
Pipeline Analysis
Disease Epidemiology

Global Viral Vaccines Market Size by Vaccine Type & CAGR (2026-2033)

Market Overview
Live Attenuated Vaccines
Inactivated Vaccines
Recombinant Vaccines
Viral Vector Vaccines
mRNA Vaccines
Others

Global Viral Vaccines Market Size by Disease Type & CAGR (2026-2033)

Market Overview
Influenza
COVID-19
Hepatitis
Human Papillomavirus (HPV)
Measles
Mumps & Rubella (MMR)
Varicella
Others

Global Viral Vaccines Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Intramuscular
Oral
Intranasal
Subcutaneous

Global Viral Vaccines Market Size by Age Group & CAGR (2026-2033)

Market Overview
Pediatric
Adult
Geriatric

Global Viral Vaccines Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Government Supply Programs
Others

Global Viral Vaccines Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Vaccination Centers
Clinics
Public Health Agencies

Global Viral Vaccines Market Size & CAGR (2026-2033)

North America (Vaccine Type, Disease Type, Route of Administration, Age Group, Distribution Channel, End User)
- US
- Canada
Europe (Vaccine Type, Disease Type, Route of Administration, Age Group, Distribution Channel, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Vaccine Type, Disease Type, Route of Administration, Age Group, Distribution Channel, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Vaccine Type, Disease Type, Route of Administration, Age Group, Distribution Channel, End User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Vaccine Type, Disease Type, Route of Administration, Age Group, Distribution Channel, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moderna
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bharat Biotech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Serum Institute of India
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sinovac Biotech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sinopharm
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CanSino Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novavax
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Seqirus
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Valneva
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CureVac
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Panacea Biotec
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biological E.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments